Get started
Author

T.M. Suter

Observed names: Suter, Thomas M, T SUTER, T Suter, T. M. Suter, T. Suter, TM Suter, Thomas Martin Suter, Thomas Suter
Observed institutions: F. Hoffmann-La Roche AG, University of Bern, Université Libre de Bruxelles, University Medical Center Groningen, Memorial Sloan Kettering Cancer Center, Genentech, University of Milan, University Hospital of Bern, Institut Jules Bordet, Centre Hospitalier Universitaire Vaudois, Breast International Group, Sorbonne Université, GZA Ziekenhuizen Campus Sint-Augustinus, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, MedSIR (Spain), Hôpital Orthopédique de la Suisse Romande, Dana-Farber Cancer Institute, Hospital Arnau de Vilanova, Vall d'Hebron Hospital Universitari, IRCCS Ospedale San Raffaele, Frontier Science Foundation-Hellas, Instituto Nacional de Câncer - INCA, Hospital Universitario Ramón y Cajal, Vall d'Hebron Institute of Oncology, Roche Pharma (Schweiz) AG (Switzerland), European Institute of Oncology, Institut Curie
OpenAlex ID: A5022787034
Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate
1995 · Christian Seiler, Thomas Martin Suter, et al. · Journal of the American College of Cardiology · 61
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
2016 · Zamorano, Jose Luis, Lancellotti, Patrizio, et al. · Zurich Open Repository and Archive (University of Zurich) · 40
P176 Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin®) in HER2-positive early breast cancer
2007 · M.S. Ewer, E.A. Perez, et al. · The Breast · 25
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
2017 · Zamorano, Jose Luis, Lancellotti, Patrizio, et al. · Zurich Open Repository and Archive (University of Zurich) · 7
Corrections to “Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab”
2019 · D. Lenihan, T. Suter, et al. · Annals of Oncology · 6
PDF
Abstract P2-15-03: Cardiac safety of trastuzumab emtansine (T-DM1) following anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive (HER2+) early-stage breast cancer (EBC): Final data from TDM4874g
2013 · IE Krop, TM Suter, et al. · Cancer Research · 4
Pooled Analysis of Cardiac Safety in Patients Treated with Pertuzumab.
2009 · T. Suter, M. Brammer, et al. · Cancer Research · 4
Assessment of trastuzumab-related cardiac dysfunction in the Herceptin Adjuvant (HERA) Trial with 3.6 years median follow- up
2009 · M. J. Procter, T. Suter, et al. · Journal of Clinical Oncology · 3
Long-term cardiac outcomes of HER2+ breast cancer patients treated in the ALTTO trial
2019 · D. Eiger, N.F. Ponde, et al. · Annals of Oncology · 2
Abstract OT1-02-03: Phase I multicenter clinical trial evaluating the combination of trastuzumab emtansine (T-DM1) and non-pegylated liposomal doxorubicin (NPLD) in HER2-positive metastatic breast cancer (MBC) (MEDOPP038 study)
2017 · E López-Miranda, E Brain, et al. · Cancer Research · 2
BACH: A randomized phase II trial of doxorubicin-cyclophosphamide (AC) versus pegylated liposomal doxorubicin (PLD)-cyclophosphamide-trastuzumab (CCH) followed by paclitaxel-trastuzumab (TH) as adjuvant therapy for HER2-positive breast cancer (BC)—Cardiac safety analysis.
2010 · D. Rayson, T. Suter, et al. · Journal of Clinical Oncology · 2
Interim Results of BACH: Randomized Phase II Trial Evaluating the Safety of Two Chemotherapy Regimens as Adjuvant Therapy in Patients with HER2-Positive Breast Cancer: PLD + Cyclophosphamide + Trastuzumab (PLD+C+H), or Doxorubicin + Cyclophosphomide (A+C), Each Followed by Paclitaxel + Trastuzumab (T+H).
2009 · D. Rayson, T. Suter, et al. · Cancer Research · 2
P110 Cardiac side effects in the HERceptin Adjuvant, (HERA) trial
2007 · T.M. Suter, M. Procter, et al. · The Breast · 2
Exercise training for cardiovascular prevention in patients with cancer
2026 · Massimo Piepoli, Alain Cohen-Solal, et al. · European Heart Journal · 1
Circulating microRNAs for early detection of therapy-related cardiac events in HER2-positive breast cancer patients: an explorative analysis from NeoALTTO
2022 · S. Pizzamiglio, C.M. Ciniselli, et al. · European Journal of Cancer · 1
Abstract P1-13-07: Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-Positive breast cancer
2018 · J Bines, E de Azambuja, et al. · Cancer Research · 1
Kardiovaskuläre Nebenwirkungen der modernen medikamentösen Krebstherapie
2010 · S Zbinden, M Bühlmann, et al. · Swiss Medical Forum ‒ Schweizerisches Medizin-Forum · 1
PDF
Effets indésirables cardiovasculaires du traitement médicamenteux monderne du cancer
2010 · S Zbinden, M Bühlmann, et al. · Forum Médical Suisse ‒ Swiss Medical Forum · 1
Prediction of mortality, bleeding, and ischaemic events in patients with cancer and acute coronary syndrome: a model development and validation study
2026 · Wenzl, Florian A., Ow, Kok Weng, et al. · Zurich Open Repository and Archive (University of Zurich)
Protective effects of the neuregulin/ErbB2 signaling system on cancer therapy-associated cardiotoxicity in adult cardiomyocytes
2008 · C ZUPPINGER, F TIMOLATI, et al. · European Journal of Heart Failure Supplements
Adjuvant therapy of HER2-positive breast cancer with trastuzumab
2008 · Beat Thürlimann, Hervé Bonnefoi, et al.
S4 The evolution of adjuvant therapies – and the heart?
2007 · T. Suter · The Breast
Rapport annuel 2002 du Groupe de Travail Biologie Cardiovasculaire
2003 · Daniel Hayoz, François Mach, et al. · Cardiovascular Medicine
121 Neuregulin-1 attenuates doxorubicin-induced degradation of myofilament structure and excitation-contraction coupling in adult cardiomyocytes
2003 · C ZUPPINGER, M TRUCILLO, et al. · European Journal of Heart Failure Supplements
Herzinsuffizienztherapie im neuen Millennium—welche Rolle spielen die Angiotensin-II-Antagonisten?
2000 · T. M. Suter, F. R. Eberli, et al. · Cardiovascular Medicine
Works count: 26
Citation count: 165
H-index: 5
I10-index: 3
Year
Topic
Type